TMPRSS2 and prostate cancer: Previous studies have established that TMPRSS2–ERG fusion is the most frequent genomic alteration in prostate cancer, present in ∼50% of cases, and that TMPRSS2–ERG fusion is an early event in disease progression (10, 33, 34).